WO2004045551A3 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
WO2004045551A3
WO2004045551A3 PCT/US2003/037017 US0337017W WO2004045551A3 WO 2004045551 A3 WO2004045551 A3 WO 2004045551A3 US 0337017 W US0337017 W US 0337017W WO 2004045551 A3 WO2004045551 A3 WO 2004045551A3
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic
pharmaceutical composition
composition
levorphanol
propoxyphene
Prior art date
Application number
PCT/US2003/037017
Other languages
French (fr)
Other versions
WO2004045551A2 (en
Inventor
Ronny Mcneil
Ricardo Mayo-Alvarez
Original Assignee
Branded Products For The Futur
Ronny Mcneil
Ricardo Mayo-Alvarez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Branded Products For The Futur, Ronny Mcneil, Ricardo Mayo-Alvarez filed Critical Branded Products For The Futur
Priority to AU2003291103A priority Critical patent/AU2003291103A1/en
Priority to EP03783692A priority patent/EP1603593A4/en
Publication of WO2004045551A2 publication Critical patent/WO2004045551A2/en
Publication of WO2004045551A3 publication Critical patent/WO2004045551A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising an analgesic or analgesic combination and a stool softener is disclosed. The analgesic is selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol, codeine, acetaminophen and combinations of these analgesics. The composition is formulated for oral administration as a liquid or solid dosage form for immediate, slow, delayed or sustained-release characteristics.
PCT/US2003/037017 2002-11-15 2003-11-17 Pharmaceutical composition WO2004045551A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003291103A AU2003291103A1 (en) 2002-11-15 2003-11-17 Pharmaceutical composition
EP03783692A EP1603593A4 (en) 2002-11-15 2003-11-17 Pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42686702P 2002-11-15 2002-11-15
US60/426,867 2002-11-15

Publications (2)

Publication Number Publication Date
WO2004045551A2 WO2004045551A2 (en) 2004-06-03
WO2004045551A3 true WO2004045551A3 (en) 2004-12-09

Family

ID=32326444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037017 WO2004045551A2 (en) 2002-11-15 2003-11-17 Pharmaceutical composition

Country Status (4)

Country Link
US (4) US7192966B2 (en)
EP (1) EP1603593A4 (en)
AU (1) AU2003291103A1 (en)
WO (1) WO2004045551A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
KR101045144B1 (en) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
EP1603593A4 (en) * 2002-11-15 2007-08-01 Branded Products For The Futur Pharmaceutical composition
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
ES2653568T3 (en) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Drug formulations for abuse prevention
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060205752A1 (en) * 2005-03-14 2006-09-14 Keith Whitehead Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid
AU2007225022A1 (en) * 2006-03-15 2007-09-20 Biotech Pharmaceuticals Pty Ltd Non-codeine opioid analgesic process and formulations
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
BRPI0923836A2 (en) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Opioid-containing oral pharmaceutical compositions and methods
WO2010099508A1 (en) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
EP2477610A1 (en) 2009-09-17 2012-07-25 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
AU2010300641B2 (en) 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
CN103370058A (en) 2010-12-22 2013-10-23 普渡制药公司 Encased tamper resistant controlled release dosage forms
CN107412173A (en) 2010-12-23 2017-12-01 普渡制药公司 Anti-distort solid oral dosage form
US9662274B2 (en) * 2014-04-11 2017-05-30 Innovative Products, Inc. Method of orally administering a treating agent over an extended period
RU2673818C2 (en) 2012-11-30 2018-11-30 Экьюра Фармасьютикалз, Инк. Self-regulated release of active pharmaceutical ingredient
MX2015010041A (en) 2013-02-05 2015-10-30 Purdue Pharma Lp Tamper resistant pharmaceutical formulations.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
US5232699A (en) * 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
US5516524A (en) * 1993-12-20 1996-05-14 The Procter & Gamble Company Laxative compositions containing bulk fiber
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
GB1583602A (en) * 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
GB2281205A (en) * 1993-08-24 1995-03-01 Euro Celtique Sa Oral opioid analgesic
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
EP1603593A4 (en) 2002-11-15 2007-08-01 Branded Products For The Futur Pharmaceutical composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
US5232699A (en) * 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5516524A (en) * 1993-12-20 1996-05-14 The Procter & Gamble Company Laxative compositions containing bulk fiber
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAZARUS H.: "A multi-investigator clinical evaluation of oral controlled-release morphine", HOSPICE J., vol. 6, no. 4, 1990, pages 1 - 15, XP002903116 *

Also Published As

Publication number Publication date
US7973048B2 (en) 2011-07-05
US8188108B2 (en) 2012-05-29
US20040151791A1 (en) 2004-08-05
US20070142421A1 (en) 2007-06-21
US20100172973A1 (en) 2010-07-08
EP1603593A2 (en) 2005-12-14
US20110230512A1 (en) 2011-09-22
AU2003291103A8 (en) 2004-06-15
WO2004045551A2 (en) 2004-06-03
US7652026B2 (en) 2010-01-26
EP1603593A4 (en) 2007-08-01
AU2003291103A1 (en) 2004-06-15
US7192966B2 (en) 2007-03-20

Similar Documents

Publication Publication Date Title
WO2004045551A3 (en) Pharmaceutical composition
HUP0102658A2 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
WO2001097780A3 (en) Pharmaceutical compositions comprising an opioid analgesic
CA2547334A1 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
WO2005032555A3 (en) Pharmaceutical combinations of hydrocodone and naltrexone
RU2009125597A (en) MEDICINES AND METHODS FOR PRODUCING AND USING THEM
CA2446738A1 (en) Abuse-resistant opioid dosage form
CA2569742A1 (en) Opioids for the treatment of the restless leg syndrome
JP2017530964A5 (en)
IL163990A0 (en) Pharmaceutical preparation containing oxycodone and naloxone
JP2011519930A5 (en)
HK1215171A1 (en) Polymer conjugates of opioid antagonists
RU2005113996A (en) METHODS OF TREATING PAIN BY INTRODUCTION OF AN ANTAGONIST OF THE NERVOUS GROWTH FACTOR AND OPIOID ANALGETIC, AND CONTAINING THEIR COMPOSITIONS
EP2305683B8 (en) Pharmaceutical dosage form comprising oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
AU2003272601B2 (en) Sustained-release opioid formulations and methods of use
AU2003302603A1 (en) Improved opioid pharmaceutical compositions
ATE500821T1 (en) EFFORTABLE FORMS OF OPIATIVES FOR ORAL USE AND METHOD FOR ADMINISTRATION OF OXYCODONE
JP2004512260A5 (en)
RU2000119778A (en) COMBINATIONS AGONIST / OPIOID ANTAGONIST
CA2323805A1 (en) Analgesic combination comprising nmda receptor antagonists and narcotic analgesics
NZ594935A (en) Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
DK1242087T3 (en) Analgesic compositions containing buprenorphine
JP2010189403A5 (en)
IL164911A0 (en) Methods and dosage forms for controlled delivery of oxycodone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003783692

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003783692

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP